Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Transplantation. 2018 Apr;102(4):e128–e136. doi: 10.1097/TP.0000000000002078

Figure 3. Chimerism in the myeloid and lymphoid lineages after DBMT.

Figure 3

With the Atgam/aCD154 regimen (triangle), the recipients failed to develop chimerism (Figure 3, triangle). By adding anti-CD8 mAb to the Atgam/aCD154 regimen, 10/12 successfully developed mixed chimerism (Figure 3, open circle). With the thymo/bela regimen, all 4 recipients successfully developed chimerism in both lymphoid and myeloid lineages (red circle).